Clinical Trial Update: Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib hydrochloride given before surgery in stage III non-small cell lung cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: Albert Einstein College of Medicine | Conditions: Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-07-08